



(12) Translation of
European patent specification

(11) NO/EP 3578193 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 38/08 (2019.01) **A61L 29/08 (2006.01)**
A61K 31/145 (2006.01) **A61P 31/04 (2006.01)**
A61K 38/10 (2006.01) **C07K 7/08 (2006.01)**

Norwegian Industrial Property Office

(45) Translation Published 2023.12.11

(80) Date of The European Patent Office Publication of the Granted Patent 2023.09.06

(86) European Application Nr. 19163975.6

(86) European Filing Date 2011.03.30

(87) The European Application's Publication Date 2019.12.11

(30) Priority 2010.10.05, GB, 201016733
2010.10.05, US, 39008110 P
2010.03.31, WO, PCT/GB10/000631

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR

(62) Divided application EP2552434, 2011.03.30

(73) Proprietor Novabiotics Limited, Unit 3 Silverburn Crescent Bridge of Don, Aberdeen AB23 8EW, Storbritannia

(72) Inventor O'NEIL, Deborah, NovaBiotics Limited Cruickshank Building Craibstone, Aberdeen, AB21 9TR, Storbritannia
MERCER, Derry, NovaBiotics Limited Cruickshank Building Craibstone, Aberdeen, AB21 9TR, Storbritannia
CHARRIER, Cedric, NovaBiotics Limited Cruickshank Building Craibstone, Aberdeen, AB21 9TR, Storbritannia

(74) Agent or Attorney Nordic Patent Service A/S, Bredgade 30, 1260 KØBENHAVN K, Danmark

(54) Title **PEPTIDES AND THEIR USE**

(56) References
Cited:
GB-A- 2 408 263, WO-A2-2008/093058, WO-A2-2007/050565, EP-A1- 2 168 590
CHEN PO-WEN ET AL: "Antibacterial activity of short hydrophobic and basic-rich peptides", AMERICAN JOURNAL OF VETERINARY RESEARCH, AMERICAN VETERINARY MEDICINE ASSOCIATION, US, vol. 64, no. 9, 1 January 2003 (2003-01-01), pages 1088-1092, XP009153337, ISSN: 0002-9645
BECKLOFF NICHOLAS ET AL: "Activity of an antimicrobial peptide mimetic against planktonic and biofilm cultures of oral pathogens", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 51, no. 11, November 2007 (2007-11), pages 4125-4132, XP002611617, ISSN: 0066-4804
JAYARAMAN A ET AL: "INHIBITING SULFATE-REDUCING BACTERIA IN BIOFILMS BY EXPRESSING THE ANTIMICROBIAL PEPTIDES INDOLICIDIN AND BACTENECIN", JOURNAL OF INDUSTRIAL MICROBIOLOGY AND BIOTECHNOLOGY, BASINGSTOKE, GB, vol. 22, 1 January 1999 (1999-01-01), pages 167-175, XP002951362, ISSN: 1367-5435, DOI: DOI:10.1038/SJ.JIM.2900627

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2007 (2007-11), BECKLOFF NICHOLAS ET AL: "Activity of an antimicrobial peptide mimetic against planktonic and biofilm cultures of oral pathogens", Database accession no. PREV200800051865 & ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 51, no. 11, November 2007 (2007-11), pages 4125-4132, ISSN: 0066-4804(print), DOI: 10.1128/AAC.00208-07

OOSTERHOF J J H ET AL: "THE INFLUENCE OF ANTIMICROBIAL PEPTIDES AND MUCOLYTICS ON THE INTEGRITY OF BIOFILMS CONSISTING OF BACTERIA AND YEASTS AS AFFECTING VOICE PROSTHETIC AIR FLOW RESISTANCES", BIOFOULING (CHUR), HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 19, no. 6, 1 December 2003 (2003-12-01), pages 347-353, XP008075548, ISSN: 0892-7014, DOI: DOI:10.1080/08927010310001612054

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Peptid som består av en aminosyresekvens valgt fra gruppen
RRRRRFFFFRFRRR (SEQ ID NO:4), RRRFRRFRRFRRR (SEQ ID NO:5),
RRRFRRFPFRFRRR (SEQ ID NO:6), RRFRRFFFFRFRRR (SEQ ID NO:7),
FRRRRFFFFRFRRR (SEQ ID NO:16), RRRRRFFFFRFRRRF (SEQ ID NO:17),
FFFFRRRRRRFRRR (SEQ ID NO:18), RRRRRFFFFFRRRR (SEQ ID NO:19),
FRRRRFFFFRRRRF (SEQ ID NO:20), RRRFRRRRRRFFFF (SEQ ID NO:23).

5 2. Peptidet ifølge krav 1, for anvendelse som et medikament.

3. Sammensetning omfattende en farmasøytisk effektiv mengde av minst ett peptid ifølge krav 1 og en farmasøytisk akseptabel bærer, eksipiens eller fortynningsmiddel.

10 4. Sammensetningen ifølge krav 3, videre omfattende cysteamin og/eller polylysin.